- Home
- LPAA vs FDMT Comparison
LPAA vs FDMT Comparison
Compare LPAA & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LPAA | FDMT |
|---|---|---|
| Founded | 2024 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.4M | 695.3M |
| IPO Year | 2024 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LPAA | FDMT |
|---|---|---|
| Price | $10.85 | $13.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $27.82 |
| AVG Volume (30 Days) | 1.1K | ★ 773.8K |
| Earning Date | 01-01-0001 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $85,209,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $56.84 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $10.44 | $6.96 |
| 52 Week High | $11.67 | $16.93 |
Technical Indicators
Market Signals| Indicator | LPAA | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 52.93 | 50.33 |
| Support Level | $10.61 | $13.39 |
| Resistance Level | $11.19 | $15.29 |
| Average True Range (ATR) | 0.01 | 0.88 |
| MACD | 0.00 | -0.12 |
| Stochastic Oscillator | 100.00 | 37.21 |
Price Performance
Historical ComparisonAbout LPAA Launch One Acquisition Corp. Class A Ordinary shares
Launch One Acquisition Corp is a blank check company.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).